BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28860823)

  • 1. Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma.
    Saji H; Sakai H; Kimura H; Miyazawa T; Marushima H; Nakamura H
    Onco Targets Ther; 2017; 10():4135-4141. PubMed ID: 28860823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
    Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
    Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
    Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is 'cured' from postoperative recurrence?
    Sekihara K; Hishida T; Yoshida J; Oki T; Omori T; Katsumata S; Ueda T; Miyoshi T; Goto M; Nakasone S; Ichikawa T; Matsuzawa R; Aokage K; Goto K; Tsuboi M
    Eur J Cardiothorac Surg; 2017 Sep; 52(3):522-528. PubMed ID: 28482033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
    Hung HY; Tseng YH; Liao CM; Chen SY; Wu TP; Lee YC; Chen YM
    Integr Cancer Ther; 2017 Mar; 16(1):126-131. PubMed ID: 27151582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
    Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
    Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer.
    Liu SR; Qiu B; Yang H; Liang Y; Wang F; Liu SL; Chen ZL; Zhang L; Liu MZ; Wang SY; Lin LF; Liu H
    Ann Surg Oncol; 2016 Jun; 23(6):2115-22. PubMed ID: 26887852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
    Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.